Mutations in Kelch-like 3 and Cullin 3 Cause Hypertension and Electrolyte Abnormalities
Authors
Affiliations
Hypertension affects one billion people and is a principal reversible risk factor for cardiovascular disease. Pseudohypoaldosteronism type II (PHAII), a rare Mendelian syndrome featuring hypertension, hyperkalaemia and metabolic acidosis, has revealed previously unrecognized physiology orchestrating the balance between renal salt reabsorption and K(+) and H(+) excretion. Here we used exome sequencing to identify mutations in kelch-like 3 (KLHL3) or cullin 3 (CUL3) in PHAII patients from 41 unrelated families. KLHL3 mutations are either recessive or dominant, whereas CUL3 mutations are dominant and predominantly de novo. CUL3 and BTB-domain-containing kelch proteins such as KLHL3 are components of cullin-RING E3 ligase complexes that ubiquitinate substrates bound to kelch propeller domains. Dominant KLHL3 mutations are clustered in short segments within the kelch propeller and BTB domains implicated in substrate and cullin binding, respectively. Diverse CUL3 mutations all result in skipping of exon 9, producing an in-frame deletion. Because dominant KLHL3 and CUL3 mutations both phenocopy recessive loss-of-function KLHL3 mutations, they may abrogate ubiquitination of KLHL3 substrates. Disease features are reversed by thiazide diuretics, which inhibit the Na-Cl cotransporter in the distal nephron of the kidney; KLHL3 and CUL3 are expressed in this location, suggesting a mechanistic link between KLHL3 and CUL3 mutations, increased Na-Cl reabsorption, and disease pathogenesis. These findings demonstrate the utility of exome sequencing in disease gene identification despite the combined complexities of locus heterogeneity, mixed models of transmission and frequent de novo mutation, and establish a fundamental role for KLHL3 and CUL3 in blood pressure, K(+) and pH homeostasis.
Evidence for Functional Regulation of the KLHL3/WNK Pathway by O-GlcNAcylation.
Hu J, Huynh D, Dunn D, Wu J, Manriquez-Rodriguez C, Zhang Q bioRxiv. 2025; .
PMID: 40060460 PMC: 11888436. DOI: 10.1101/2025.02.27.640596.
Choi H, Jung I, Kim S Antioxidants (Basel). 2025; 14(1).
PMID: 39857434 PMC: 11761572. DOI: 10.3390/antiox14010100.
Bowley G, Irving S, Hoefer I, Wilkinson R, Pasterkamp G, Darwish H Sci Rep. 2024; 14(1):30130.
PMID: 39627337 PMC: 11615307. DOI: 10.1038/s41598-024-77370-1.
Davion J, Coku I, Wissocq A, Genet A, Poupart J, Defebvre L Heliyon. 2024; 10(21):e39891.
PMID: 39553548 PMC: 11566686. DOI: 10.1016/j.heliyon.2024.e39891.
Hyperkalaemic acidosis: blood pressure is the diagnostic clue.
Zieg J, Thomasova D, Libik M, Sumnik Z, Bockenhauer D Pediatr Nephrol. 2024; 40(4):967-970.
PMID: 39527282 PMC: 11885314. DOI: 10.1007/s00467-024-06590-4.